|Mice of this transgenic strain express tetracycline-controlled transactivator protein (tTA) in in stem and progenitor cells of bone marrow and can be used in the tet-off system to induce expression of target genes in bitransgenic offspring.|
Type Congenic; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Generation N7+N1F2pN1
Donating Investigator Daniel G. Tenen, Beth Israel Deaconess Medical Center
Hemizygotes are viable, fertile, normal in size, and do not display any behavioral abnormalities. Hemizygotes express tetracycline-controlled transactivator protein (tTA) in bone marrow hematopoietic stem cells (HSC) and in common myeloid progenitors (CMP)). tTA activity also is detected in lung. Little to no tTA activity is detected in thymus, lymph node, intestine or spleen. When bred to other transgenic mice carrying a gene of interest coupled to a tetracycline-responsive promoter element (TRE; tetO), expression of the target gene in the bitransgenic offspring can be induced by withdrawal of tetracycline or doxycycline. This strain represents an effective tool for generating bitrangenic animals to study inducible gene expression in blood stem and progenitor cells.
These mice were originally designed to be bred with transgenic mice harboring a TRE-BCR-ABL1 transgene (Stock No. 006202), creating bitransgenic offspring as a model for studies of the Philadelphia chromosome and inducible chronic myeloid leukemia.
A transgenic construct consisting of the SV40 minimal promoter, rabbit beta-globin intron 2, and the 3' enhancer sequence from the murine T-cell acute lymphocytic leukemia 1 gene (Tal1, formerly called homolog of human stem cell leukemia gene or SCL) was designed to direct expression of the tetracycline-regulated transactivator, tTA. The construct was injected into the pronucleus of "BDF" (C57BL/6 x DBA/2 F1 hybrid) eggs, which subsequently were implanted into pseudopregnant foster mothers. Transgenic mice were bred to generate founder line 19. In 2004, mice were bred to a "tetO-cre" transgenic mouse on an unidentified background. Subsequently, mice were selected for the Tal1-tTA transgene (and against tetO-cre) while backcrossing to FVB/N for approximately 7-9 generations prior to arrival at the Jackson Laboratory. The donating investigators note that tissues from these mice can transplant into FVB/N mice without rejection.
|Considerations for Choosing Controls|
Strains carrying Tg(Tal1-tTA)19Dgt allele
017722 B6.Cg-Tg(Tal1-tTA)19Dgt/JView Strains carrying Tg(Tal1-tTA)19Dgt (1 strain)Strains carrying other alleles of SV40
002319 B6.Cg-Tg(BCL2)22Wehi/J 002320 B6.Cg-Tg(BCL2)25Wehi/J 002321 B6.Cg-Tg(BCL2)36Wehi/J 010914 B6.Cg-Tg(Emu-TXLNA)1Amjr/J 002318 C.Cg-Tg(BCL2)22Wehi/J 003477 C57BL/6J-Tg(SV)419Bri/J 003476 C57BL/6J-Tg(SV)427Bri/J 002233 C57BL/6J-Tg(SV)7Bri/J 012256 CB6-Tg(Rbp3-SV40)IT-2Jjw/Mmjax 003268 FVB-Tg(IRS1)1Mhep/J 018322 STOCK Tg(Cp-EGFP)25Gaia/ReyaJ 020942 STOCK Tg(Cp-HIST1H2BB/Venus)47Hadj/J 006553 STOCK Tg(SMN2)89Ahmb Smn1tm1Msd Tg(H2-K1-tsA58)6Kio Tg(SMN2*delta7)4299Ahmb/JView Strains carrying other alleles of SV40 (13 strains)Strains carrying other alleles of tTA
008079 129S-Ppargtm2(tTA)Yba/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 011008 B6.129P2(Cg)-Gt(ROSA)26Sortm1(tTA)Roos/J 009602 B6.129S4(Cg)-Kcnn2tm2Jpad/J 009603 B6.129S4-Kcnn3tm1Jpad/J 008227 B6.129S4-Ppargtm3(tTA)Yba/J 016868 B6.Cg-Ssttm1.2(tTA2)Hze/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003563 B6.Cg-Tg(Cebpb-tTA)5Bjd/J 003767 B6.Cg-Tg(Eno2tTA)5021Nes/J 003763 B6.Cg-Tg(Eno2tTA)5030Nes/J 018306 B6.Cg-Tg(Fos-tTA,Fos-EGFP*)1Mmay/J 005964 B6.Cg-Tg(GFAP-tTA)110Pop/J 002618 B6.Cg-Tg(MMTVtTA)1Mam/J 008284 B6.Cg-Tg(Scg2-tTA)1Jt/J 023970 B6.Cg-Tg(Sirpa-tTA)AUmri/J 023971 B6.Cg-Tg(Sirpa-tTA)SUmri/J 006361 B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J 017754 B6;129-Omptm1(tTA)Gogo/J 007585 B6;129S4-Npytm2Rpa/J 002709 B6;C3-Tg(TettTALuc)1Dgs/J 003010 B6;CBA-Tg(Camk2a-tTA)1Mmay/J 008344 B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J 010573 B6;SJL-Tg(Prl-tTA)6-5Jek/J 008082 B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J 008603 C.129P2(B6)-Gt(ROSA)26Sortm1(tTA)Roos/J 010712 C57BL/6-Tg(Camk2a-tTA)1Stl/J 013585 FVB-Tg(Cdh5-tTA)D5Lbjn/J 005625 FVB-Tg(Pcp2-tTA)3Horr/J 025105 FVB.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003170 FVB.Cg-Tg(Myh6-tTA)6Smbf/J 005942 FVB/N-Tg(Pf4-tTA/VP16)42Kra/J 004937 NOD.Cg-Tg(Ins2-tTA)1Doi/DoiJ 006999 STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J 008335 STOCK Foxa2tm1.1(rtTa)Moon/J 008600 STOCK Gt(ROSA)26Sortm1(tTA)Roos/J 024108 STOCK Igs7tm93.1(tetO-GCaMP6f)Hze Tg(Camk2a-tTA)1Mmay/J 005701 STOCK Pdx1tm1Macd/J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 003271 STOCK Tg(CMV-tTA)3Bjd/J 024854 STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-MAPT*P301L)#Kha/J 018124 STOCK Tg(Prnp-tTA)F959Sbp/J 009606 STOCK Tg(Six2-EGFP/cre)1Amc/J 003275 STOCK Tg(tetL)1Bjd/J 003274 STOCK Tg(tetNZL)2Bjd/JView Strains carrying other alleles of tTA (45 strains)
View Research ApplicationsResearch ApplicationsThis mouse can be used to support research in many areas including:
Chronic Myelogenous Leukemia
Increased Tumor Incidence
Developmental Biology Research
Lymphoid Tissue Defects
Immunology, Inflammation and Autoimmunity Research
Lymphoid Tissue Defects
Tetop Tet System
myeloma and hybridoma production
Mutagenesis and Transgenesis
Mutagenesis and Transgenesis: Tetop Tet System
Tet Expression Systems
tTA/rtTA Expressing Strains
|Allele Name||transgene insertion 19, Daniel G Tenen|
|Allele Type||Transgenic (Transactivator)|
|Common Name(s)||SCLtTA; SCLtTA stg; Scl-tTA;|
|Mutation Made By||Daniel Tenen, Beth Israel Deaconess Medical Center|
|Strain of Origin||(C57BL/6 x DBA/2)F1|
|Site of Expression||Expresses tTA in bone marrow-derived hematopoietic stem cells (HSC) and common myeloid progenitors (CMP). tTA activity also is detected in lung.|
|Expressed Gene||tTA, tetracycline-controlled transactivator, E. coli|
|The tetracycline-resistance gene (TetR), arose from chemically mutated Escherichia coli genome which was screened for tetracycline dependence (Gossen and Bujard, 1992). TetR was fused at the C-terminus with the viral co-activator, virion protein 16 of the herpes simplex virus (VP-16). The tetracycline-inhibitable transcription factor is a component of a bigenic system that allows doxycycline (a tetracycline analog) regulatable expression of genes that are under the direction of the tetracycline responsive promoter (TetOp)promoter.|
|Promoter||SV40, E mu enhancer, SV40|
|Molecular Note||The transgene consists of the SV40 minimal promoter, rabbit beta-globin intron 2, and the 3' enhancer sequence from the mouse T-cell acute lymphocytic leukemia gene driving expression of the tetracycline-regulated transactivator. [MGI Ref ID J:96511]|
Koschmieder S; Gottgens B; Zhang P; Iwasaki-Arai J; Akashi K; Kutok JL; Dayaram T; Geary K; Green AR; Tenen DG; Huettner CS. 2005. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105(1):324-34. [PubMed: 15331442] [MGI Ref ID J:96511]
Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Muller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T. 2013. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells. Blood 121(20):4175-83. [PubMed: 23543457] [MGI Ref ID J:198207]
Chen CI; Koschmieder S; Kerstiens L; Schemionek M; Altvater B; Pscherer S; Gerss J; Maecker HT; Berdel WE; Juergens H; Lee PP; Rossig C. 2012. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 26(3):465-74. [PubMed: 21904381] [MGI Ref ID J:181529]
Eiring AM; Harb JG; Neviani P; Garton C; Oaks JJ; Spizzo R; Liu S; Schwind S; Santhanam R; Hickey CJ; Becker H; Chandler JC; Andino R; Cortes J; Hokland P; Huettner CS; Bhatia R; Roy DC; Liebhaber SA; Caligiuri MA; Marcucci G; Garzon R; Croce CM; Calin GA; Perrotti D. 2010. miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 140(5):652-65. [PubMed: 20211135] [MGI Ref ID J:160777]
Hamilton A; Helgason GV; Schemionek M; Zhang B; Myssina S; Allan EK; Nicolini FE; Muller-Tidow C; Bhatia R; Brunton VG; Koschmieder S; Holyoake TL. 2012. Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119(6):1501-10. [PubMed: 22184410] [MGI Ref ID J:181724]
Harb JG; Neviani P; Chyla BJ; Ellis JJ; Ferenchak GJ; Oaks JJ; Walker CJ; Hokland P; Roy DC; Caligiuri MA; Marcucci G; Huettner CS; Perrotti D. 2013. Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia 27(10):1996-2005. [PubMed: 23670294] [MGI Ref ID J:201846]
Moore CR; Liu Y; Shao C; Covey LR; Morse HC 3rd; Xie P. 2012. Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in mice. Leukemia 26(5):1122-7. [PubMed: 22033491] [MGI Ref ID J:188983]
Reynaud D; Pietras E; Barry-Holson K; Mir A; Binnewies M; Jeanne M; Sala-Torra O; Radich JP; Passegue E. 2011. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20(5):661-73. [PubMed: 22094259] [MGI Ref ID J:178950]
Schemionek M; Elling C; Steidl U; Baumer N; Hamilton A; Spieker T; Gothert JR; Stehling M; Wagers A; Huettner CS; Tenen DG; Tickenbrock L; Berdel WE; Serve H; Holyoake TL; Muller-Tidow C; Koschmieder S. 2010. BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells. Blood 115(16):3185-95. [PubMed: 20053753] [MGI Ref ID J:160797]
Schepers K; Pietras EM; Reynaud D; Flach J; Binnewies M; Garg T; Wagers AJ; Hsiao EC; Passegue E. 2013. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 13(3):285-99. [PubMed: 23850243] [MGI Ref ID J:201668]
Sengupta A; Arnett J; Dunn S; Williams DA; Cancelas JA. 2010. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood 116(1):81-4. [PubMed: 20407032] [MGI Ref ID J:162808]
Welner RS; Amabile G; Bararia D; Czibere A; Yang H; Zhang H; Pontes LL; Ye M; Levantini E; Di Ruscio A; Martinelli G; Tenen DG. 2015. Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells. Cancer Cell 27(5):671-81. [PubMed: 25965572] [MGI Ref ID J:221401]
Zhang B; Ho YW; Huang Q; Maeda T; Lin A; Lee SU; Hair A; Holyoake TL; Huettner C; Bhatia R. 2012. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 21(4):577-92. [PubMed: 22516264] [MGI Ref ID J:189328]
Animal Health ReportsProduction of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.
Breeding & Husbandry When maintaining a live colony, transgenic mice are bred together or to wildtype siblings.
|Pricing for USA, Canada and Mexico shipping destinations|
Cryopreserved Mice - Ready for Recovery
Price (US dollars $) Cryorecovery* $2625.00
At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.
Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|Pricing for International shipping destinations|
Cryopreserved Mice - Ready for Recovery
Price (US dollars $) Cryorecovery* $3412.50
Cryorecovery - Standard.
Progeny testing is not required.
|Considerations for Choosing Controls|
|Control Pricing Information for Genetically Engineered Mutant Strains.|
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.